EGFR Targeted Gemcitabine PLGA Nanoparticles for Pancreat...
Gupta, Swati / Aggarwal, Sahil
Adenocarcinoma of the exocrine pancreas is the fourth leading cause of cancer deaths in the United States. Currently, surgery is the only treatment, although due to its late presentation, only 9% to 15% of patients are suitable for surgery. The median survival for all stages of pancreatic cancer is 3 to 5 months from diagnosis. The underlying problem in the use of anticancer drugs is their toxicity and poor bioavailability. It is expected that...